THERAPEUTIC PROTEINS AND ORAL VACCINES MARKET ANALYSIS

Regional Analysis

Global Therapeutic Proteins and Oral Vaccines Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global therapeutic proteins and oral vaccines market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The North America therapeutic proteins and oral vaccines market is expected to witness significant growth in the coming years, driven by the increasing growth strategies by market players such as signing distribution agreement in the region. For instance, in November 2021, Pfizer Inc. announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, the U.S. government will acquire 10 million treatment courses to be delivered by Pfizer beginning later this year and concluding in 2022.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa